Avidity Biosciences, Inc.

Avidity Biosciences is a biotechnology company dedicated to revolutionizing the delivery of RNA therapeutics. They are developing a novel class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies. This unique platform allows them to target and treat diseases previously unreachable with traditional RNA therapies, particularly in areas like muscle diseases, cardiology, and immunology.

Avidity Biosciences focuses on addressing the root causes of diseases by developing AOCs for various conditions, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and other rare diseases. Their innovative approach has led to successful clinical trials and is promising a new era of effective treatments for patients suffering from these debilitating conditions.

Avidity Biosciences offers a hybrid work environment, which means employees can split their time between working in the office and working remotely. This gives employees the flexibility to choose a work arrangement that best suits their needs. The company is also headquartered in San Diego, CA, making it a desirable location for many employees.

Avidity Biosciences offers competitive compensation and benefits to its employees, including the opportunity for annual and spot bonuses, stock options and RSUs, and a 401(k) with an employer match. The company also provides a comprehensive wellness program that includes coverage for medical, dental, vision, and LTD, as well as four weeks of time off. In addition, Avidity is committed to learning and development, providing a variety of internally developed programs, opportunities for job-specific training, and an education reimbursement program.

Avidity Biosciences is a biotechnology company dedicated to profoundly improving the lives of people affected by serious diseases by delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). Their proprietary AOC platform combines the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target diseases previously unreachable with existing RNA therapies. Their innovative pipeline focuses on three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD), as well as expanding into areas like cardiology and immunology through internal discovery efforts and key partnerships.

Avidity Biosciences cultivates a culture that is collaborative, agile, and driven by a shared passion for improving people's lives through innovative RNA therapeutics. They emphasize diversity and inclusion, valuing the unique perspectives of each team member. They promote a high-performance environment that fosters innovation, creativity, and excellence, encouraging employees to be proactive, adaptable, and accountable. This culture is further strengthened by their commitment to employee growth and development, providing opportunities for learning, training, and career advancement.

Avidity Biosciences is committed to building a diverse team with experience in rare disease and RNA therapies. The company emphasizes the importance of a talented, diverse and collaborative team to not only grow the company, but also to reflect the communities they serve. They are dedicated to employing and retaining an inclusive workforce at all levels of the organization to ensure that different backgrounds and perspectives are being heard and integrated. Through their BeAVID values – Agile, Visionary, Integrated and Diverse – they consistently challenge themselves to excel and deliver on their commitment to patients and their families.